Results 151 to 160 of about 31,541 (206)

Pure red cell aplasia post-SARS-CoV-2 infection: a case report in an HIV-positive patient. [PDF]

Front Med (Lausanne)
Wang Y, Tang S, Bian R, Wen Y.
europepmc   +1 more source

Lopinavir Derivative as Potent P-gp Inhibitor Enables Delivery through HPMA Copolymer Conjugates and Overcoming Tumor Chemoresistance to Conventional Cytostatic Drugs. [PDF]

Biomacromolecules
Starenko D, Kostka L, Behalova K, Kotrchova L, Subr V, Kovarova J, Roubalova R, Sirova M, Etrych T, Kovar M.   +9 more
europepmc   +1 more source

Metabolic syndrome and its risk factors among adults living with HIV receiving antiretroviral therapy in Zambia: an ambidirectional cohort study. [PDF]

Sci Rep
Hamooya BM, Bosomprah S, Masenga SK, Mutengo KH, Cheelo C, Siame L, Simushi P, Mwakyoma T, Mudenda J, Mutale W, Halwiindi H, Bedimo R, Shrestha S, Chanda C, Heimburger DC, Lipworth L.   +15 more
europepmc   +1 more source

Drug-Target Interaction Prediction via Dual-Interaction Fusion. [PDF]

Molecules
Li X, Li Z, Wei B, Zeng Y.
europepmc   +1 more source

Insights into Antiviral Candidates against Oropouche Virus: A Molecular Dynamics Study. [PDF]

ACS Phys Chem Au
Colherinhas G, Cardoso WB.
europepmc   +1 more source

Coagulation is associated with renal function decline and chronic kidney disease in people living with HIV in South Africa. [PDF]

Front Nephrol
Choshi J, Mokoena H, Mabhida SE, Flepisi BT, Steel HC, Mokgalaboni K, Phoswa WN, Maarman G, Nkambule BB, Dludla PV, Hanser S.   +10 more
europepmc   +1 more source

Pharmacokinetics of dexamethasone in tuberculosis meningitis

Calderin JM, Resendiz-Galvan JE, Abdelgawad N, Davis A, Stek C, Wiesner L, Meintjes G, Wilkinson RJ, Denti P, Wasserman S.   +9 more
europepmc   +1 more source

Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial [PDF]

Intensive Care Medicine, 2021
Purpose To study the efficacy of lopinavir-ritonavir and hydroxychloroquine in critically ill patients with coronavirus disease 2019 (COVID-19).
Alistair D Nichol, Lindsay Berry, Frank M Brunkhorst   +2 more
exaly   +9 more sources

Some of the next articles are maybe not open access.

Related searches:

Lopinavir

Drugs, 2000
Lopinavir is a protease inhibitor with high specificity for HIV-1 protease. Ritonavir strongly inhibits lopinavir metabolism; coadministration of lopinavir and ritonavir in healthy volunteers increased the area under the lopinavir plasma concentration-time curve >100-fold.
M, Hurst, D, Faulds
  +5 more sources

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 [PDF]

Clinical Microbiology and Infection, 2021
Objectives: We evaluated the clinical, virological and safety outcomes of lopinavir/ritonavir, lopinavir/ritonavir–interferon (IFN)-β-1a, hydroxychloroquine or remdesivir in comparison to standard of care (control) in coronavirus 2019 disease (COVID-19 ...
Florence Ader, Nathan Peiffer-Smadja, Julien Poissy   +2 more
exaly   +2 more sources